Vaxxinova US (formerly Epitopix) announces Vaxxon SRP Klebsiella as the new name for KLEBVax SRP, a mastitis vaccine recently marketed by Huvepharma USA.

Vaxxinova said Vaxxon SRP Klebsiella is identical to KLEBVax and remains the only vaccine licensed by the U.S. Department of Agriculture for the management of mastitis caused by Klebsiella pneumoniae spp.

“As the vaccine’s manufacturer, Vaxxinova is excited Vaxxon SRP Klebsiella is returning to our own expanding family of vaccines,” said Tim Hopson, Vaxxinova US director of sales and technical services. “Vaxxon SRP Klebsiella is a key tool to help producers and veterinarians have a more specific mastitis control strategy."

The vaccine, formerly marketed by AgriLabs/Huvepharma, will now be marketed by Vaxxinova through distribution to dairy veterinarians and producers. Customer service and technical support will come directly from Vaxxinova. More information about the vaccine is available at www.vaxxinova.us.com.

Dairy losses due to Klebsiella-induced mastitis are expensive and increasing, according to Dr. Robert Rust, Vaxxinova senior technical services veterinarian. “Case detection has increased more than 90% over the past 10-plus years among herds in the Northeast dairy belt,” Rust said. “The combined cull and death among infected cows is as high as 80%. However, recent field trials report dramatic reductions in cases of Klebsiella-induced mastitis, with some herds nearing 100% reduction, where Vaxxon SRP Klebsiella has been introduced.”

Vaxxinova US discovers and develops original veterinary vaccines to improve animal health and food safety, building upon a foundation of proprietary SRP technologies, in an environment that values scientific creativity.